NCT02192346 is a Phase 1 clinical trial of 2.4 mg/kg α-TEA in Metastatic Carcinoma, sponsored by Providence Health & Services.

Who is sponsoring NCT02192346?

NCT02192346 is sponsored by Providence Health & Services.

What drugs are being tested in NCT02192346?

Interventions in NCT02192346: 2.4 mg/kg α-TEA, 4.8 mg/kg α-TEA, 8.0 mg/kg α-TEA, 9.6 mg/kg α-TEA, 12 mg/kg α-TEA, 16.8 mg/kg α-TEA, 19.2 mg/kg α-TEA, 22.3 mg/kg α-TEA, 26.8 mg/kg α-TEA.

What condition does NCT02192346 study?

NCT02192346 studies Metastatic Carcinoma, Metastatic Sarcoma, Metastatic Lymphoma.

Is NCT02192346 still recruiting?

NCT02192346 is currently completed. Last updated 17 August 2018.

Last reviewed 2018-08-17 · How we verify

NCT02192346

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

α-TEA in Advanced Cancer

Completed Phase 1 Last updated 17 August 2018

What this trial tests

Phase 1 trial testing 2.4 mg/kg α-TEA in Metastatic Carcinoma in 17 participants. Completed in 8 May 2018.

Timeline

4 August 2014

Primary endpoint
11 December 2017

8 May 2018

Quick facts

Lead sponsor	Providence Health & Services
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	4 August 2014
Primary completion	11 December 2017
Estimated completion	8 May 2018
Sites	5 locations across United States

Drugs / interventions tested

2.4 mg/kg α-TEA
4.8 mg/kg α-TEA — full drug profile →
8.0 mg/kg α-TEA
9.6 mg/kg α-TEA
12 mg/kg α-TEA — full drug profile →
16.8 mg/kg α-TEA — full drug profile →
19.2 mg/kg α-TEA — full drug profile →
22.3 mg/kg α-TEA
26.8 mg/kg α-TEA — full drug profile →

Conditions studied

Metastatic Carcinoma — all drugs for Metastatic Carcinoma →
Metastatic Sarcoma — all drugs for Metastatic Sarcoma →
Metastatic Lymphoma — all drugs for Metastatic Lymphoma →

Sponsor

Providence Health & Services — full company profile →

Who can join

18 and older, any sex, with Metastatic Carcinoma or Metastatic Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood. Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA.
Redmond WL, Kasiewicz MJ, Akporiaye ET. · · 2023 · cited 1× · PMID 36911733 · DOI 10.3389/fimmu.2023.1057702
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts : National Harbor, MD, USA. 9-13 November 2016
Althammer S, Steele K, Rebelatto M, Tan T, et al · · 2016
Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer
Curti B, Akporiaye E, Sutcliffe K, Bahjat K, et al · · 2015 · DOI 10.1186/2051-1426-3-s2-p148

Verify or expand the search:

Other Providence Health & Services trials

Trials by the same sponsor.

NCT06175000 — Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Parti · Phase 2 · recruiting
NCT04987996 — GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients · Phase 2 · withdrawn
NCT05349890 — Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) · Phase 1 · active not recruiting
NCT04796584 — Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication · terminated
NCT04417699 — SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02192346 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Providence Health & Services
Last refreshed: 17 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02192346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing